Muhlenkamp & Co’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-50,803
| Closed | -$2.96M | – | 36 |
|
|
2020
Q4 | $2.96M | Buy |
50,803
+643
| +1% | +$38.8K | 1.19% | 29 |
|
|
2020
Q3 | $3.17M | Buy |
50,160
+745
| +2% | +$51.7K | 1.64% | 25 |
|
|
2020
Q2 | $3.8M | Buy |
+49,415
| New | +$3.79M | 2.03% | 24 |
|
|
2019
Q4 | $2.56M | Sell |
39,475
-93,134
| -70% | -$6.07M | 1.12% | 30 |
|
|
2019
Q3 | $8.4M | Buy |
132,609
+58
| +0% | +$3.79K | 4.1% | 8 |
|
|
2019
Q2 | $8.96M | Sell |
132,551
-388
| -0.3% | -$25.5K | 4.35% | 9 |
|
|
2019
Q1 | $8.64M | Buy |
+132,939
| New | +$8.84M | 4.09% | 10 |
|
|
2018
Q3 | $10.5M | Sell |
135,401
-823
| -0.6% | -$62.2K | 4.47% | 7 |
|
|
2018
Q2 | $9.65M | Sell |
136,224
-86,153
| -39% | -$6.08M | 3.68% | 12 |
|
|
2018
Q1 | $16.8M | Buy |
222,377
+1,764
| +0.8% | +$140K | 6.08% | 2 |
|
|
2017
Q4 | $15.8M | Sell |
220,613
-3,534
| -2% | -$268K | 4.67% | 5 |
|
|
2017
Q3 | $18.2M | Sell |
224,147
-1,538
| -0.7% | -$118K | 5.72% | 3 |
|
|
2017
Q2 | $16M | Sell |
225,685
-40
| -0% | -$2.66K | 5% | 5 |
|
|
2017
Q1 | $15.3M | Buy |
225,725
+12,730
| +6% | +$895K | 4.7% | 4 |
|
|
2016
Q4 | $15.3M | Sell |
212,995
-1,500
| -0.7% | -$111K | 4.81% | 4 |
|
|
2016
Q3 | $17M | Sell |
214,495
-2,505
| -1% | -$203K | 6.41% | 2 |
|
|
2016
Q2 | $18.1M | Sell |
217,000
-990
| -0.5% | -$87.9K | 7.07% | 2 |
|
|
2016
Q1 | $20M | Buy |
217,990
+15
| +0% | +$1.35K | 8.17% | 2 |
|
|
2015
Q4 | $22.1M | Sell |
217,975
-15
| -0% | -$1.56K | 6.63% | 3 |
|
|
2015
Q3 | $21.4M | Sell |
217,990
-630
| -0.3% | -$70K | 6.28% | 3 |
|
|
2015
Q2 | $25.6M | Sell |
218,620
-120
| -0.1% | -$13.1K | 5.54% | 2 |
|
|
2015
Q1 | $21.5M | Sell |
218,740
-205
| -0.1% | -$20.8K | 4.52% | 3 |
|
|
2014
Q4 | $20.6M | Buy |
218,945
+12,595
| +6% | +$1.3M | 4.14% | 3 |
|
|
2014
Q3 | $22M | Buy |
206,350
+61,635
| +43% | +$6.04M | 3.97% | 4 |
|
|
2014
Q2 | $12M | Sell |
144,715
-47,300
| -25% | -$3.68M | 2.12% | 19 |
|
|
2014
Q1 | $13.6M | Sell |
192,015
-780
| -0.4% | -$61.2K | 2.39% | 18 |
|
|
2013
Q4 | $14.5M | Buy |
192,795
+5,415
| +3% | +$377K | 2.52% | 16 |
|
|
2013
Q3 | $11.8M | Buy |
187,380
+855
| +0.5% | +$51.1K | 2.34% | 18 |
|
|
2013
Q2 | $9.56M | Buy |
+186,525
| New | +$9.72M | 1.99% | 22 |
|
Other funds holding GILD
Muhlenkamp & Co's GILD Position: Q1 2021 in Review
Muhlenkamp & Co sold out of Gilead Sciences (GILD) in Q1 2021, closing a stake of 50,803 shares — an estimated $2.96M sold.
Muhlenkamp & Co first reported a position in GILD in Q2 2013 and held it in 29 quarters. The position peaked at $25.6M in Q2 2015. 1,567 funds tracked by Wall St. Rank hold GILD as of Q1 2021.
- Muhlenkamp & Co reported no remaining Gilead Sciences position as of Q1 2021 after selling out during the quarter.
- Muhlenkamp & Co sold 50,803 Gilead Sciences shares in Q1 2021, an estimated $2.96M.
- Muhlenkamp & Co first reported a position in Gilead Sciences in Q2 2013 and held it in 29 quarters.
- Muhlenkamp & Co's Gilead Sciences position peaked at $25.6M in Q2 2015.
- 1,567 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2021.
Based on Muhlenkamp & Co's 13F filing for Q1 2021, filed 18 Aug 2021.